Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

Pfizer announced that a late-stage trial in lung cancer for a Seagen-derived ADC, sigvotatug vedotin, has failed. Phase I ...

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

One of the antibody-drug conjugates at the heart of Pfizer's $43 billion acquisition of Seagen three years ago has failed a ...

Pfizer is entering 2024 with a much larger oncology organization thanks to its Seagen buyout. But it's still actively seeking ADC-focused deals, its oncology chief said in an interview. (Pfizer) San ...

An established but promising group of cancer drugs was a red-hot market in 2023, and more acquisitions and advancements are expected in the year ahead. That was one clear takeaway from the JPMorgan ...

Pfizer (PFE) has been actively dealmaking and receiving FDA approvals for new products and new indications in the past couple of years, but that has all been overshadowed by its runaway success with ...

On January 16, 2024, the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademark Office issued a Final Written Decision in a post-grant review (PGR) (PGR2021-00030) of claims in ...

Tiragolumab's esophageal cancer readout, the latest episode in Daiichi Sankyo and Seagen's patent fight, and an antibody-drug conjugate specialist's fundraising ...

SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. That was one clear ...